Patents Assigned to SK BIOSCIENCE CO., LTD.
-
Patent number: 11951162Abstract: The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.Type: GrantFiled: April 18, 2019Date of Patent: April 9, 2024Assignee: SK BIOSCIENCE CO., LTD.Inventors: Hun Kim, Dong Soo Ham, Jin-Hwan Shin, Kyung-jun An, Sung-hyun Kim
-
Patent number: 11911452Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: September 10, 2021Date of Patent: February 27, 2024Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Publication number: 20240059730Abstract: A method for purifying a target protein in high yield is disclosed. The target protein includes a membrane protein. The purification method optimizes crushing and elution conditions during processes of separation and purification of membrane proteins, and when using the method to purify membrane proteins, the membrane proteins can be purified in a higher yield that is not less than 100 times compared to conventional homogenizer or sonic pulverization process. In addition, the purification method render removals of nuclei, peroxisomes, and lysosomes, thereby reducing DNA contamination and protein damage by proteases.Type: ApplicationFiled: January 25, 2022Publication date: February 22, 2024Applicant: SK BIOSCIENCE CO., LTD.Inventors: Hak KIM, Taewoo KWON, Ki-Weon SEO
-
Publication number: 20240042008Abstract: The present invention provides a recombinant antigen protein for preventing SARS-coronavirus-2 infection, comprising a polypeptide derived from an S1 subunit of a spike protein of SARS-coronavirus-2 and a polypeptide constituting a tetanus toxin (TT) epitope P2 domain, and a vaccine composition comprising the same.Type: ApplicationFiled: October 27, 2021Publication date: February 8, 2024Applicant: SK BIOSCIENCE CO., LTD.Inventors: Ki-weon SEO, Teawoo KWON, Eun-som KIM, Chi-Yong KIM, Yoonjae LEE, Seung-hye HONG
-
Patent number: 11883483Abstract: The present invention relates to a method of preparing an influenza working virus seed stock, a method of increasing infectivity of an influenza working virus seed stock, a method of preparing an influenza vaccine using the seed stock, an influenza vaccine prepared by the method, and an influenza working virus seed stock having increased infectivity.Type: GrantFiled: July 5, 2018Date of Patent: January 30, 2024Assignee: SK BIOSCIENCE CO., LTD.Inventors: Yun Hee Kim, Yong Wook Park, Dong Soo Ham, Hwan Ui Jung, Hun Kim
-
Patent number: 11241489Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: August 4, 2017Date of Patent: February 8, 2022Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
-
Patent number: 11224652Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: August 4, 2017Date of Patent: January 18, 2022Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
-
Patent number: 11147864Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: February 4, 2019Date of Patent: October 19, 2021Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
-
Patent number: 11123417Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.Type: GrantFiled: February 4, 2019Date of Patent: September 21, 2021Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga